Details of the Drug Combinations

General Information of This Drug (ID: DM2EJM3)

Drug Name
AKB-6548   DM2EJM3
Indication
Disease Entry ICD 11 Status REF
Anaemia 3A90 Phase 3 [1]
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

9 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
AKB-6548 + Simvastatin DC2DVIE Simvastatin Drug Interaction Potentiation [2]
AKB-6548 + Pravastatin DC38281 Pravastatin Drug Interaction Potentiation [2]
AKB-6548 + Probenecid DC5IVOK Probenecid Drug Interaction Potentiation [3]
AKB-6548 + Furosemide DC5JKS7 Furosemide Drug Interaction Potentiation [4]
AKB-6548 + Rabeprazole DCCJ7XS Rabeprazole Drug Interaction Potentiation [5]
AKB-6548 + Rosuvastatin DCDGXNZ Rosuvastatin Drug Interaction Potentiation [2]
AKB-6548 + Rifampicin DCDNBV8 Rifampicin Drug Interaction Potentiation [3]
AKB-6548 + Digoxin DCSN04H Digoxin Drug Interaction Potentiation [4]
AKB-6548 + Adefovir DCVZK1N Adefovir Drug Interaction Potentiation [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DrugCom(s)

References

1 ClinicalTrials.gov (NCT03242967) Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) (TRILOGY). U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT03801733) Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin
3 ClinicalTrials.gov (NCT03801746) Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin
4 ClinicalTrials.gov (NCT03801759) Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide
5 ClinicalTrials.gov (NCT03789032) Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat